

## DEPARTMENT OF JUSTICE

## Antitrust Division

**Notice Pursuant to the National Cooperative Research and Production Act of 1993—Unified Extensible Firmware Interface Forum**

Notice is hereby given that, on February 5, 2014, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Unified Extensible Firmware Interface Forum (“UEFI Forum”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the name and principal place of business of the standards development organization and (2) the nature and scope of its standards development activities. The notifications were filed for the purpose of invoking the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to Section 6(b) of the Act, the name and principal place of business of the standards development organization is: Unified Extensible Firmware Interface Forum, Beaverton, OR. The nature and scope of UEFI Forum’s standards development activities are: UEFI Forum members, through the Forum’s Working Groups, develop, manage, and promote UEFI Specifications and the Advanced Configuration and Power Interface (“ACPI”) Specification—which are voluntary consensus standards under the Act—and Test Suites to test compliance with these Specifications. The purpose of these Specifications is to simplify and secure platform initialization and firmware boot up operations. UEFI Forum’s members are industry-leading technology companies, whose consensus efforts promote business and technological efficiency, improve performance and security, facilitate interoperability between devices, platforms and systems, and enable next-generation technologies to emerge.

**Patricia A. Brink,**

*Director of Civil Enforcement, Antitrust Division.*

[FR Doc. 2014–05451 Filed 3–12–14; 8:45 am]

**BILLING CODE 4410–CW–P**

## DEPARTMENT OF JUSTICE

## Drug Enforcement Administration

**Importer of Controlled Substances; Notice of Registration; Cerilliant Corporation**

By Notice dated November 5, 2013, and published in the **Federal Register** on November 18, 2013, 78 FR 69130, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665–2402, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances:

Drug	Schedule
Methaqualone (2565) .....	I
JWH-250 (6250) .....	I
SR-18 also known as RCS-8 (7008) .....	I
XLR11 (7011) .....	I
JWH-019 (7019) .....	I
AKB48 (7048) .....	I
JWH-081 (7081) .....	I
SR-19 also known as RCS-4 (7104) .....	I
JWH-122 (7122) .....	I
UR-144 (7144) .....	I
AM-2201 (7201) .....	I
JWH-203 (7203) .....	I
Parahexyl (7374) .....	I
2C-T-2 (7385) .....	I
JWH-398 (7398) .....	I
5-Methoxy-3,4-methylenedioxy-amphetamine (7401) .....	I
N-Hydroxy-3,4-methylenedioxy-amphetamine (7402) .....	I
Bufotenine (7433) .....	I
N-Ethyl-1-phenylcyclohexylamine (7455) .....	I
1-(1-Phenylcyclohexyl)pyrrolidine (7458) .....	I
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470) .....	I
2C-D (7508) .....	I
2C-E (7509) .....	I
2C-H (7517) .....	I
2C-I (7518) .....	I
2C-C (7519) .....	I
2C-N (7521) .....	I
2C-P (7524) .....	I
2C-T-4 (7532) .....	I
AM-694 (7694) .....	I
Codeine methylbromide (9070) ....	I
Acetylmetadadol (9601) .....	I
Allylprodine (9602) .....	I
Alphacetylmetadadol except levopropylmetadadol (9603) .....	I
Alphameprodine (9604) .....	I
Alphamethadol (9605) .....	I
Betacetylmetadadol (9607) .....	I
Betameprodine (9608) .....	I
Betamethadol (9609) .....	I
Betaprodine (9611) .....	I
Hydroxypethidine (9627) .....	I
Noracymethadol (9633) .....	I
Norlevorphanol (9634) .....	I
Normethadone (9635) .....	I
Para-Fluorofentanyl (9812) .....	I

Drug	Schedule
3-Methylfentanyl (9813) .....	I
Alpha-methylfentanyl (9814) .....	I
Acetyl-alpha-methylfentanyl (9815) .....	I
Beta-hydroxyfentanyl (9830) .....	I
Beta-hydroxy-3-methylfentanyl (9831) .....	I
Alpha-methylthiofentanyl (9832) ...	I
3-Methylthiofentanyl (9833) .....	I
Thiofentanyl (9835) .....	I
Lisdexamfetamine (1205) .....	II
Glutethimide (2550) .....	II
Nabilone (7379) .....	II
1-Phenylcyclohexylamine (7460) .....	II
1-Piperidinocyclohexanecarbonitrile (8603) .....	II
Alphaprodine (9010) .....	II
Hydrocodone (9193) .....	II
Levomethorphan (9210) .....	II
Levorphanol (9220) .....	II
Noroxymorphone (9668) .....	II
Racemethorphan (9732) .....	II
Remifentanyl (9739) .....	II
Carfentanyl (9743) .....	II
Tapentadol (9780) .....	II

The company plans to import the listed controlled substances for manufacture and distribution to their research and forensic customers conducting drug testing and analysis.

The DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Cerilliant Corporation to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA has investigated Cerilliant Corporation to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: February 19, 2014.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2014–05499 Filed 3–12–14; 8:45 am]

**BILLING CODE 4410–09–P**